huahaipharm(SH:600521) Zheng Quan Zhi Xing·2025-07-24 16:20Core Points - Zhejiang Huahai Pharmaceutical Co., Ltd. has announced a delay in the "Formulation Digital Intelligent Manufacturing Construction Project" to December 2026, as approved by the board of directors on July 24, 2025 [1][4] - The delay only involves adjustments to the project timeline and does not change the use of raised funds or negatively impact the company's normal operations or shareholder interests [1][4][5] - The total amount raised from the issuance of shares was approximately CNY 600 million, with a net amount of approximately CNY 582 million after deducting issuance costs [1][2] Fundraising Overview - The company raised CNY 599,999,994.54 by issuing 41,152,263 shares at a price of CNY 14.58 per share, with net proceeds of CNY 582,319,365.51 after deducting issuance costs [1][2] - The funds are allocated to two main projects: the "Formulation Digital Intelligent Manufacturing Construction Project" and working capital, with total planned investments of CNY 172,274.12 million [2] Project Delay Details - The original completion date for the "Formulation Digital Intelligent Manufacturing Construction Project" was set for July 2025, now postponed to December 2026 due to the project's large scale and external factors [3] - The project aims to integrate various information systems to create a fully automated production line with a designed capacity of 15 billion tablets per year [3] Impact of Delay - The delay is a strategic decision based on objective project conditions and will not materially affect the implementation of the project or the company's operations [4][5] - The company emphasizes that the delay does not involve changes to the investment content, purpose, total amount, or implementation entity of the project [4][5] Approval Process - The delay was approved through a series of meetings, including the board of directors and independent directors, and does not require shareholder approval [4][5][6]